Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity In Vivo

Neoplasia

Volumn 13, Issue 3, 2011, Pages 217-229

  Canu, Bastianina ^a,b   Fioravanti, Anna ^a,b   Orlandi, Paola ^a,b   Di Desidero, Teresa ^a,b   Alì, Greta ^a   Fontanini, Gabriella ^a   Di Paolo, Antonello ^a   del Tacca, Mario ^a   Danesi, Romano ^a   Bocci, Guido ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; AXITINIB; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; THROMBOSPONDIN 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ABCG2 GENE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATP7A GENE; CELL LEVEL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN SECRETION; TUMOR REGRESSION; TUMOR XENOGRAFT;

EID: 79952433928     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.101334     Document Type: Article

References (53)

1. Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, Letourneau R, Bajetta E, Pithavala Y, Bycott P, et al. (2008). Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 371, 2101-2108.
2. Kelly RJ and Rixe O (2009). Axitinib-a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. Target Oncol 4, 297-305.
3. Solowiej J, Bergqvist S, McTigue MA, Marrone T, Quenzer T, Cobbs M, Ryan K, Kania RS, Diehl W, and Murray BW (2009). Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib. Biochemistry 48, 7019-7031.
4. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, et al. (2008). Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14, 7272-7283.
5. Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, et al. (2007). AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 25, 319-327.
6. Ma J andWaxman DJ (2009). Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib. Clin Cancer Res 15, 578-588.
7. Fenton BM and Paoni SF (2007). The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature. Cancer Res 67, 9921-9928.
8. Fenton BM and Paoni SF (2009). Alterations in daily sequencing of axitinib and fractionated radiotherapy do not affect tumor growth inhibition or pathophysiological response. Radiat Res 171, 606-614.
9. Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD, and McDonald DM (2006). Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res 66, 1434-1445.
10. Ma J and Waxman DJ (2008). Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol Cancer Ther 7, 79-89.
11. O'Reilly EM (2009). Pancreatic adenocarcinoma: new strategies for success. Gastrointest Cancer Res 3, S11-S15.
12. Bocci G, Fioravanti A, Orlandi P, Bernardini N, Collecchi P, Del Tacca M, and Danesi R (2005). Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. Br J Cancer 93, 319-330.
13. Bocci G, Danesi R, Marangoni G, Fioravanti A, Boggi U, Esposito I, Fasciani A, Boschi E, Campani D, Bevilacqua G, et al. (2004). Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. Eur J Pharmacol 498, 9-18.
14. Bruns CJ, Shinohara H, Harbison MT, Davis DW, Nelkin G, Killion JJ, McConkey DJ, Dong Z, and Fidler IJ (2000). Therapy of human pancreatic carcinoma implants by irinotecan and the oral immunomodulator JBT 3002 is associated with enhanced expression of inducible nitric oxide synthase in tumorinfiltrating macrophages. Cancer Res 60, 2-7.
15. Dineen SP, Sullivan LA, Beck AW, Miller AF, Carbon JG, Mamluk R, Wong H, and Brekken RA (2008). The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer 8, 352.
16. Mishra G, Butler J, Ho C, Melin S, Case LD, Ennever PR, Magrinat GC, Bearden JD, Minotto DC, Howerton R, et al. (2005). Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. Am J Clin Oncol 28, 345-350.
17. Rocha Lima CM, Sherman CA, Brescia FJ, Brunson CY, and Green MR (2001). Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer. Oncology (Williston Park) 15, 46-51.
18. Bissery MC, Vrignaud P, Lavelle F, and Chabot GG (1996). Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs 7, 437-460.
19. Rosen LS (1998). Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers. Oncology (Williston Park) 12, 103-109.
20. Agrawal S, Kandimalla ER, Yu D, Ball R, Lombardi G, Lucas T, Dexter DL, Hollister BA, and Chen SF (2002). GEM 231, a second-generation antisense agent complementary to protein kinase A RIa subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts. Int J Oncol 21, 65-72.
21. DeRosier LC, Buchsbaum DJ, Oliver PG, Huang ZQ, Sellers JC, Grizzle WE, Wang W, Zhou T, Zinn KR, Long JW, et al. (2007). Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clin Cancer Res 13, 5535s-5543s.
22. Kusuhara H and Sugiyama Y (2007). ATP-binding cassette, subfamily G (ABCG family). Pflugers Arch 453, 735-744.
23. Candeil L, Gourdier I, Peyron D, Vezzio N, Copois V, Bibeau F, Orsetti B, Scheffer GL, Ychou M, Khan QA, et al. (2004). ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int J Cancer 109, 848-854.
24. Takara K, Kitada N, Yoshikawa E, Yamamoto K, Horibe S, Sakaeda T, Nishiguchi K, Ohnishi N, and Yokoyama T (2009). Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride. Cancer Lett 278, 88-96.
25. Furukawa T, Komatsu M, Ikeda R, Tsujikawa K, and Akiyama S (2008). Copper transport systems are involved in multidrug resistance and drug transport. Curr Med Chem 15, 3268-3278.
26. Owatari S, Akune S, Komatsu M, Ikeda R, Firth SD, Che XF, Yamamoto M, Tsujikawa K, Kitazono M, Ishizawa T, et al. (2007). Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res 67, 4860-4868.
27. Chou TC (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58, 621-681.
28. Bocci G, Falcone A, Fioravanti A, Orlandi P, Di Paolo A, Fanelli G, Viacava P, Naccarato AG, Kerbel RS, Danesi R, et al. (2008). Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer 98, 1619-1629.
29. Allegrini G, Falcone A, Fioravanti A, Barletta MT, Orlandi P, Loupakis F, Cerri E, Masi G, Di Paolo A, Kerbel RS, et al. (2008). A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. Br J Cancer 98, 1312-1319.
30. Simon PO Jr, McDunn JE, Kashiwagi H, Chang K, Goedegebuure PS, Hotchkiss RS, and Hawkins WG (2009). Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma. Int J Cancer 125, 942-951.
31. Bressenot A, Marchal S, Bezdetnaya L, Garrier J, Guillemin F, and Plenat F (2009). Assessment of apoptosis by immunohistochemistry to active caspase-3, active caspase-7, or cleaved PARP in monolayer cells and spheroid and subcutaneous xenografts of human carcinoma. J Histochem Cytochem 57, 289-300.
32. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, et al. (2010). Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102, 1555-1577.
33. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, et al. (2008). Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26, 4708-4713.
34. Schiller JH, Larson T, Ou SH, Limentani S, Sandler A, Vokes E, Kim S, Liau K, Bycott P, Olszanski AJ, et al. (2009). Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 27, 3836-3841.
35. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, and Dutcher JP (2009). Phase II study of axitinib in sorafenibrefractory metastatic renal cell carcinoma. J Clin Oncol 27, 4462-4468.
36. Sharma S, Abhyankar V, Burgess RE, Infante J, Trowbridge RC, Tarazi J, Kim S, Tortorici M, Chen Y, and Robles RL (2010). A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann Oncol 21, 297-304.
37. Ferrara N (2010). Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 21, 21-26.
38. Bates SE, Medina-Perez WY, Kohlhagen G, Antony S, Nadjem T, Robey RW, and Pommier Y (2004). ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins. J Pharmacol Exp Ther 310, 836-842.
39. Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, and Fu LW (2009). Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett 279, 74-83.
40. Shukla S, Robey RW, Bates SE, and Ambudkar SV (2009). Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 37, 359-365.
41. Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, and Bates SE (2010). Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos 38, 1371-1380.
42. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP, and Iruela-Arispe ML (2007). Autocrine VEGF signaling is required for vascular homeostasis. Cell 130, 691-703.
43. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, and Kerbel RS (2007). Multiple circulating proangiogenic factors induced by sunitinib malate are tumorindependent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 104, 17069-17074.
44. Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, and Motzer RJ (2007). Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J TranslMed 5, 32.
45. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, et al. (2006). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24, 16-24.
46. Pena C, Lathia C, Shan M, Escudier B, and Bukowski RM (2010). Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res 16, 4853-4863.
47. Norden-Zfoni A, Desai J, Manola J, Beaudry P, Force J, Maki R, Folkman J, Bello C, Baum C, DePrimo SE, et al. (2007). Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinibresistant gastrointestinal stromal tumor. Clin Cancer Res 13, 2643-2650.
48. Mukohara T, Nakajima H, Mukai H, Nagai S, Itoh K, Umeyama Y, Hashimoto J, and Minami H (2010). Effect of axitinib (AG-013736) on fatigue, thyroidstimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Sci 101, 963-968.
49. Bussolati B, Assenzio B, Deregibus MC, and Camussi G (2006). The proangiogenic phenotype of human tumor-derived endothelial cells depends on thrombospondin-1 downregulation via phosphatidylinositol 3-kinase/Akt pathway. J Mol Med 84, 852-863.
50. Niu Q, Perruzzi C, Voskas D, Lawler J, Dumont DJ, and Benjamin LE (2004). Inhibition of Tie-2 signaling induces endothelial cell apoptosis, decreases Akt signaling, and induces endothelial cell expression of the endogenous anti-angiogenic molecule, thrombospondin-1. Cancer Biol Ther 3, 402-405.
51. Ji Y, Hayashi K, Amoh Y, Tsuji K, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, Bouvet M, and Hoffman RM (2007). The camptothecin derivative CPT-11 inhibits angiogenesis in a dual-color imageable orthotopic metastatic nude mouse model of human colon cancer. Anticancer Res 27, 713-718.
52. Kamiyama H, Takano S, Tsuboi K, and Matsumura A (2005). Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 α (HIF-1α)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J Cancer Res Clin Oncol 131, 205-213.
53. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, and Kerbel RS (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239.